Navigation Links
GeneThera Extends its Reach Overseas
Date:6/16/2009

Results from Pharma Finance 2009

ARVADA, Colo., June 16 /PRNewswire-FirstCall/ -- GeneThera, Inc. (OTC: GTHR.PK). GeneThera, as a service and responsibility to our shareholders, is addressing our recent events.

GeneThera Inc. recently attended Pharma Finance 2009, a Biotechnology, Medical Devices, and world public and private Finance Conference in Rome, Italy on June 4-5.

Pharma Finance is an international event addressing new technologies for Life Sciences, concentrating on Biotechnology, finance, nano-technology and innovative materials.

The Lazio Region and Sviluppo Lazio S.p.A. jointly organized Pharma Finance, in collaboration with the Ministry for International Commerce, ICE, Filas S.p.A. and the Zangani Investor Community.

During the two-day event big pharma, small and medium size enterprises, research and university centers presented their products, research projects and technologies. The Conference foreign delegation session fostered the internationalization process taken by many businesses, to develop international cooperation; the presence of Business Angels and Venture Capitalist provided useful information to new entrepreneurial activities.

Dr. Milici comments, "We felt that this particular conference provided us the opportunity to meet with companies outside the United States, such as Canada and Italy, but also emerging nations such as The United Arab Emirates and Singapore to name a few. We feel that the safety of the world's food system can be protected by our proprietary technology, which stems from our vast expertise in creating solutions from microbiology and genetics."

As a result of the attendance at Pharma Finance 2009, GeneThera is in talks with the University of Rome, who is also working on a vaccine for Johne's disease and looking to collaborate on the activities in Mexico. In addition, GeneThera will be looking to expand its investor base by applying for the TSX Venture Exchange after speaking with the exchange's vice president.

As discussions progress, the company will release more details.

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Arvada, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Richard Dopkin at JR Dopkin & Associates LLC at 516-884-3200.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.


'/>"/>
SOURCE GeneThera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STC.UNM Signs License Option Agreement With GeneThera for E. coli O157:H7 Vaccine
2. [video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.nets 3-Minute Press Show
3. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
4. Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009
5. BVF Acquisition LLC Extends Avigen Tender Offer to April 3, 2009
6. BVF Acquisition LLC Extends Avigen Tender Offer to March 6, 2009
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. GlaxoSmithKline Reduces Minimum Tender Condition and Extends Tender Offer To Acquire Genelabs Technologies, Inc.
9. GlaxoSmithKline Extends Tender Offer for Genelabs Technologies, Inc.
10. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
11. Ziehm Imaging Extends its Training Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... AESKU.GROUP, an innovation ... Systeme & Technologien GmbH, thereby expanding its product portfolio to include allergy and ... urticaria, asthma, atopic eczema or a food allergy. Allergies are escalating to epidemic ...
(Date:6/22/2017)... Yorba Linda, Ca (PRWEB) , ... June 22, 2017 , ... ... labs worldwide. It took 20 years until the first data on cross-contamination of human ... cell lines has been an increasing issue in cell culture labs and is associated ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has ... her latest book, Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your ... physiological effect on men. ”The logical next step, in my estimation, was to scientifically ...
(Date:6/20/2017)... ... , ... Do More with OHAUS , With the launch of the new ... weighing industry, to extending its expertise across the entire laboratory to a range of ... allowing for its customers to 'Do More' in the lab. , Efficiency ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
Breaking Biology News(10 mins):